CD8A and neoplasm: Moreover, recent evidence suggests that nintedanib can boost the efficacy of immunotherapy by upregulating MHC-I and PD-L1 expression and increasing the infiltration of CD8+ T cells and DC cell maturation to enhance tumor sensitivity to immunotherapy in both in vivo and in vitro experiments (45, 46), which warrants further clinical evaluation.